In 2021, PharmEasy was everything Indian healthtech investors wanted to believe in. A $5.6 billion valuation. A landmark acquisition of Thyrocare — one of India's most respected diagnostic brands — for ₹4,546 crore. An IPO on the horizon. Five founders who had built, seemingly from nothing, a digital health platform that would revolutionise how Indians bought medicine, accessed diagnostics, and interacted with the healthcare system.
By 2024, the same company had written down its own valuation by 90%, watched its founders exit one by one, and was pledging its most valuable asset — the Thyrocare shares it had paid dearly for — to raise emergency debt. The distance between those two points is one of the most instructive cautionary tales in Indian startup history. But here is the less-told part of the story: the company is fighting back.
THE CORPORATE STRUCTURE: THREE LAYERS YOU NEED TO UNDERSTAND
The confusion around PharmEasy, Thyrocare, and API Holdings starts with the structure — so let's clear it up simply.
API Holdings Limited sits at the top. It is the ultimate parent company — unlisted, private, and the entity through which investors including Prosus, TPG, Temasek, and Ranjan Pai's family office hold their stake. API Holdings controls everything below it. Docon Technologies Private Limited is a 100% subsidiary of API Holdings. Docon is the legal entity that actually holds and manages the Thyrocare stake on behalf of the group.
PharmEasy is the consumer-facing brand — the online pharmacy, B2B medicine supply platform, and teleconsultation service — that most people associate with the group. It operates under API Holdings.
Thyrocare Technologies Limited is the listed diagnostics company — publicly traded on BSE and NSE — in which Docon holds a majority stake. Thyrocare is the group's most profitable, most credible, and most liquid asset.
THE THYROCARE ACQUISITION: A DEAL THAT CHANGED EVERYTHING
In June 2021, API Holdings announced the acquisition of 66.1% stake in Thyrocare Technologies from its founder Dr A. Velumani and affiliates, at ₹1,300 per share — a total outlay of ₹4,546 crore. Docon Technologies, a 100% subsidiary of API, was designated as the acquiring entity, with an open offer made for an additional 26% stake. As part of the arrangement, Dr Velumani acquired a minority non-controlling stake of less than 5% in API Holdings itself.
At the time, the deal was celebrated as transformational — combining PharmEasy's digital distribution with Thyrocare's pan-India diagnostic network. In hindsight, it was transformational in a different way: it became the asset that kept the group alive when everything else went wrong.
Where is Dr Velumani now? The founder who built Thyrocare from ₹15,000 in savings into a listed diagnostics giant sold his controlling stake and stepped back from executive leadership. He is no longer involved in Thyrocare's day-to-day operations or management. His legacy — the lab network, the franchise model, the brand — continues, but under entirely new management.
WHAT WENT WRONG: THE COLLAPSE OF THE ORIGINAL PLAN
The IPO that was supposed to crown PharmEasy's rise was never filed. The company's aggressive expansion — into B2C pharmacy, B2B supply, diagnostics, and teleconsultation simultaneously — created a cost structure that its revenue could not support. Goodwill impairments, early NCD redemption charges, and mounting losses forced a dramatic reassessment.
API Holdings managed to reduce its loss by 40% to ₹1,516.8 crore in FY25 from ₹2,531 crore in FY24. However, operating revenue was almost flat at ₹5,872 crore versus ₹5,664 crore in FY24. Flat revenue with a 40% loss reduction is progress — but it is not the growth story that justified a $5.6 billion valuation.
In FY24, API Holdings revenue had fallen 15% year-on-year to ₹5,564 crore — a sharp contraction that triggered the broader strategic reset. The valuation markdown that followed — from $5.6 billion to approximately $1.5 billion — was one of the most dramatic in Indian startup history.
THE THYROCARE STAKE SALES: ASSET MONETISATION AS SURVIVAL
With the IPO off the table and cash running thin, the group turned to its most valuable listed asset.
On October 24, 2025, Docon Technologies sold approximately 53.3 lakh Thyrocare shares — representing 10% of total paid-up share capital — at an average price of ₹1,252 per share, generating ₹667.69 crore. Post-sale, Docon's promoter shareholding reduced from approximately 70.98% to 60.93%. Docon continues as Thyrocare's promoter. Simultaneously, API Holdings issued ₹1,700 crore in new Non-Convertible Debentures, pledging 60.93% of Thyrocare shares — held through Docon — as security. Despite redeeming its Series 2 NCDs worth ₹500 crore in October 2025, the Series 1 NCDs of ₹1,200 crore remain outstanding, held by 360 ONE Prime and Micro Labs among others.
In plain terms: Thyrocare's shares are both being sold to raise cash and being pledged as collateral for debt. The group is simultaneously monetising its best asset and using it as a financial backstop. This is a high-wire act — it works as long as Thyrocare's stock price holds up and the operational turnaround delivers.
THE LEADERSHIP OVERHAUL: FOUNDERS OUT, PROFESSIONALS IN
The most significant structural change at API Holdings in 2025 was not financial — it was human.
In January 2025, co-founders Dharmil Sheth, Dhaval Shah, and Hardik Dedhia stepped back from executive roles to launch All Home, an architecture and interior design venture backed by Bessemer Venture Partners. In August 2025, the last remaining operational co-founder Siddharth Shah stepped down as CEO, transitioning to Vice Chairman.
Rahul Guha — who was already serving as MD and CEO of Thyrocare — was appointed MD and CEO of API Holdings effective August 27, 2025, while continuing to lead Thyrocare simultaneously. One person now leads both the listed subsidiary and the unlisted parent. That is an unusual arrangement — but it reflects the group's core strategic logic: Thyrocare is the engine, and the rest of the group needs to be rebuilt in its image.
Following the exit of all founders, API Holdings is now effectively controlled by its institutional investors: Ranjan Pai's family office, Prosus, TPG, and Temasek. The founder-led era is definitively over. What follows is a professional management turnaround — with institutional shareholders demanding a credible path to profitability before entertaining any IPO conversation.
THE NEW PLAYBOOK: PROFIT FIRST, GROWTH SECOND
Rahul Guha's strategy is sharply different from the growth-at-all-costs approach that characterised the founders' era.
API Holdings has set a clear goal: turn profitable by March 2027. The "One Group" strategy — driving internal procurement from 40% to 85%, cross-selling across the group's customer base, and rolling out higher-margin private label products — has already delivered margin improvement. The focus has shifted to chronic patients who value savings over speed, plus new services including at-home vaccinations and elder care.
The revenue mix reveals both the progress and the problem. B2B sales through Retailio contributed ₹3,343 crore — 56.9% of FY25 revenue. Thyrocare's diagnostics contributed ₹757 crore (12.9%). But the consumer-facing B2C pharmacy marketplace — the business that defined the PharmEasy brand — contributed just ₹344 crore, or 5.9% of total revenue.
The brand that consumers know — the online pharmacy that ran those memorable ads — is actually the smallest revenue contributor. The real PharmEasy is a B2B medicine supply business built on Retailio, supported by a diagnostic arm through Thyrocare. The consumer brand is a distribution channel, not a profit centre.
THYROCARE: THE ONE BUSINESS THAT ACTUALLY WORKS
While PharmEasy's core business struggles, Thyrocare has been performing remarkably well — and deserves separate recognition.
Thyrocare posted revenue of ₹687.5 crore in FY25 — up 20% from ₹571.88 crore in FY24. Profit grew 30% to ₹90.75 crore. In Q2 FY26, Thyrocare reported an 80% surge in net profit and 23% revenue growth, also announcing a 2:1 bonus share issue and interim dividend of ₹7 per share. The stock surged 16% on that announcement.
Thyrocare's 100% NABL accreditation, franchise expansion, and improving test volumes are creating the exact profitable cash-generative business that the group desperately needs at its core. The irony is that the acquisition the market questioned most heavily in 2021 — buying a profitable diagnostics company with startup cash — turned out to be the decision that kept the group alive.
VALUATION AND WHAT COMES NEXT
API Holdings' latest private market valuation stands at approximately $1.5 billion — a 90% reduction from its peak of $5.6 billion. The listed Thyrocare business alone has a market capitalisation of approximately ₹6,500–7,000 crore — and API Holdings controls 60.93% of it through Docon. At current market prices, the Thyrocare stake alone is worth approximately ₹4,000 crore to API Holdings — not far from what was paid for the entire 66.1% stake in 2021.
The path to valuation recovery runs through a single word: profitability. The target is EBITDA and net profit positive, excluding Thyrocare, by March 2027. If that is achieved, the IPO conversation restarts — from a position of financial credibility rather than aspiration. PharmEasy had earlier revived IPO ambitions, but the market and its own investors have made clear that an IPO requires demonstrated profitability, not a promise of it.
The story of API Holdings is ultimately a story about what happens when a startup grows faster than its foundations can support — and then has to spend three painful years rebuilding those foundations from scratch. The founders who dreamed the original dream have moved on. The institution they built is still standing, being held together by a pledged diagnostics company, institutional investor patience, and a new CEO with a mandate to do what the founders could not: make it profitable.
